Luspatercept for Lower Risk MDS

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
40 patients (estimated)
Sponsors
MD Anderson Cancer Center
Tags
Erythroid Maturation Agent (EMA), Red Blood Cell Stimulant, Growth Factor
Trial Type
Supportive
Last Update
4 weeks ago
SparkCures ID
1845
NCT Identifier
NCT06113302

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.